PARMA, Italy, March 30, 2026 (GLOBE NEWSWIRE)-- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare ...

Experts discuss the effect and safety of lomitapide and evinacumab in treating patients with HoFH. Erin Michos, MD, MHS: Lomitapide [Juxtapid] is an oral microsomal transfer protein inhibitor. It’s ...

Evinacumab is highlighted as a new therapy for treating patients with homozygous FH. Eliot Brinton, MD: There has been a recent breakthrough in HoFH [homozygous familial hypercholesterolemia] ...

Please provide your email address to receive an email when new articles are posted on . Lomitapide was approved for treatment of homozygous familial hypercholesterolemia in children as young as 2 ...

The APH-19 trial enrolled a total of 46 patients 5 to 17 years of age with HoFH who had a mean LDL-C at baseline of 436 mg/dL. Lomitapide was associated with statistically significant reductions in ...

DUBLIN, Ireland, and Boston MA, March 30, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel ...

MANNHEIM, Germany — Lomitapide, which reduces lipoprotein production in the liver, could help manage pediatric homozygous familial hypercholesterolemia (HoFH), suggest results of a trial that showed ...

Aegerion Pharmaceuticals, Inc. (AEGR) is an emerging biotech company focusing on developing drugs for fatal rare diseases. Its sole drug candidate, lomitapide, is designed to treat Homozygous Familial ...

Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of ...